financetom
Business
financetom
/
Business
/
ERIC Eurozone PMI Shows Little Relief From Stagnation Just Yet, Says ING
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ERIC Eurozone PMI Shows Little Relief From Stagnation Just Yet, Says ING
Feb 21, 2025 3:39 AM

06:03 AM EST, 02/21/2025 (MT Newswires) -- After a decent start to 2024, last year ended on a weak note as the eurozone economy fell back into an all-too-familiar stagnation, said ING.

The start of 2025 shows signs of stabilization, with Friday's composite PMI for the eurozone at 50.2 in February, unchanged from last month, wrote the bank in a note. This suggests continued muddling through around 0%.

That's not great, but there's at least no sign of activity deteriorating further, pointed out ING. The weakness was concentrated in France as Germany and the rest of the eurozone showed expanding output.

Manufacturing has shown some signs of bottoming out, with the manufacturing output PMI increasing from 47.1 to 48.7. This still indicates contraction, but the pace of the decline is slowing, stated the bank.

Services are still showing growth, but this is despite weakening new business. Consumer confidence crept up a bit in February but remained solidly below the long-term average. The downbeat consumer is causing household consumption to remain muted amid global uncertainty, which holds back service activity, added ING.

With orders still declining, businesses indicating that they are reducing workforces and possibly disruptive tariffs on the table, the outlook remains very uncertain for the coming months. Stock markets have become more upbeat about Europe recently, but improving sentiment is difficult to justify looking at the short-term outlook, according to the bank.

Even though the European Central Bank seems convinced that inflation is under control, cost pressures do continue to creep up for businesses. In February, the PMI again flagged rising input costs that are being priced through to the consumer to some extent.

Then again, it's a stretch to expect a marked flare-up of medium-term inflation in the current weak demand environment. ING sees the ECB continuing to lower rates for the time being.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved